

Allelic Variation in *HLA-DRB1* is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing *in Vitro*

Christian Hammer, Jane Ruppel, Julie Hunkapiller, Ira Mellman, Valerie Quarmby

Genentech, Inc., South San Francisco, CA 94080, USA

Correspondence: Christian Hammer, hammer.christian@gene.com

Abstract

The treatment of diseases with biologic agents can result in the formation of anti-drug antibodies (ADA). The occurrence of ADA were reported for atezolizumab, an anti-PD-L1 monoclonal antibody widely used as immunotherapeutic treatment in cancer patients. Although drivers for ADA formation are unknown, a role for antigen presentation is likely, and variation in human leukocyte antigen (HLA) genes has been shown to be associated with occurrence of ADA for several biologics. Here, we performed an HLA-wide association study in 1,982 patients treated with atezolizumab across 8 clinical trials. On average, 29.8% of patients were ADA positive (N = 591, range of 13.5% - 38.4%), and 14.6% of patients were positive for ADA that were neutralizing *in vitro* (NAb, N = 278, range of 6.4% - 21.9%). We found statistically significant associations between HLA class II alleles and ADA status. The top-associated alleles were *HLA-DRB1*01:01* for all ADA ($p = 3.4 \times 10^{-5}$, odds ratio = 1.96), and *HLA-DQA1*01:01* when considering NAb only ($p = 2.8 \times 10^{-7}$, OR = 2.31). Both alleles occur together on a common HLA haplotype, and the ADA association was explained by the NAb subset. In conclusion, our study showed that HLA class II genotype contributes to the risk of developing ADA, and specifically NAb, in patients treated with atezolizumab, but suggests that genetic factors are not sufficient as clinically meaningful predictors.

Introduction

Immune checkpoint blockade (ICB) using therapeutic antibodies has significantly improved clinical outcome and quality of life across a range of cancer indications.¹ However, the administration of therapeutic proteins (biologics) can lead to unwanted immune responses in the form of anti-drug antibodies (ADA),² which have indeed been observed for all approved immune checkpoint inhibitors (ICI).^{3,4} Reported ADA incidences for atezolizumab, a monoclonal antibody used as immunotherapeutic treatment in cancer patients, are higher than those for other anti PD1/PD-L1 antibodies when they are used as single agent therapy.^{3,4} A subset of ADA-positive patients develop neutralizing antibodies (NAb). By definition, NAb can inhibit the function of a protein therapeutic *in vitro* regardless of their *in vivo* clinical relevance.² The impact of atezolizumab ADA and NAb on clinical outcomes is currently under evaluation.

The role of patient-related baseline prognostic factors in mediating the risk for ADA formation, and the need to take these into account when assessing potential ADA impact is under active investigation.⁵⁻⁷ Given their role in the presentation of peptide antigens to T cells, it seems likely that inherited genetic variation in Human Leukocyte Antigen (HLA) molecules would play a role in ADA development. HLA proteins show a high degree of allelic variation, and the amino acid composition of their antigen-binding groove determines the spectrum of peptides presented.⁸ Indeed, the risk of ADA development during treatment with therapeutic proteins such as interferon beta (IFN β) or with anti-tumor necrosis factor (anti-TNF) antibodies was previously reported to be associated with specific HLA class II alleles.⁹⁻¹² We therefore hypothesized that the variable presentation of atezolizumab peptides via HLA molecules could contribute to ADA formation. Here, we present what is, to our knowledge, the largest genetic association study for an immunogenicity phenotype, involving a total of 1982 cancer patients treated with atezolizumab. We found statistically significant associations of HLA class II alleles with both ADA and NAb status, and fine-mapped both associations to a single amino-acid residue in the HLA-DR β 1 subunit.

Methods

Studies and subjects

Patient data from eight atezolizumab phase III clinical trials were included in this analysis (Table 1). Clinical trial results have been previously reported, and the clinical trial protocols have been provided as supplementary materials in the original study publications.^{13–21} Patients included in this study signed an optional Research Biosample Repository (RBR) Informed Consent Form (ICF) and provided whole blood samples. By signing the optional RBR ICF, patients provided informed consent for analysis of inherited and non-inherited genetic variation from whole blood samples. Ethics Committees (EC) and Institutional Review Boards (IRB) in each country and each study site for each clinical trial approved the clinical trial protocol, the main study ICF, and the RBR ICF. The EC and IRB for each clinical trial, country, and study site are provided as Supplementary Data.

Detection and analysis of ADA and NAb status

ADA and NAb incidences were systematically assessed in atezolizumab-treated patients in all studies. Analytical methods were developed and run in accordance with industry best practices and health authority guidelines.^{2,22–26} Based on a tiered testing strategy, all ADA samples were tested in an ADA screening assay.²⁷ Samples that were deemed ADA positive were subsequently analyzed in a NAb assay. The NAb assay utilized a ligand binding format, and was designed in accordance with industry best practices.²⁸ Samples were pretreated prior to NAb analysis to separate ADA from drug in the sample. The resulting ADA solution was then analyzed for its ability to prevent the binding of drug to the PD-L1 target. Based on this, ADA positive samples were deemed NAb positive, NAb negative or NAb indeterminate. As with all NAb assays, ADA/drug stoichiometry does not reflect *in vivo* conditions, and consequently samples that are found to be neutralizing *in vitro* may not impact drug efficacy.²

Whole Genome Sequencing and HLA genotyping

Genomic DNA was extracted from blood samples using the DNA Blood400 kit (Chemagic) and eluted in 50 μ L Elution Buffer (EB, Qiagen). DNA was sheared (Covaris LE220) and sequencing libraries were prepared using the TruSeq Nano DNA HT kit (Illumina Inc.). Libraries were sequenced at Human Longevity (San Diego, CA, USA). 150bp paired-end whole-genome sequencing (WGS) data was generated to an average read depth of 30 \times using the HiSeq platform (Illumina X10, San Diego, CA, USA) and processed using the Burrows Wheeler Aligner (BWA)/Genome Analysis Toolkit (GATK) best practices pipeline.^{29–31} Short reads were mapped to hg38/GRCh38 (GCA_000001405.15), including alternate assemblies, using an alt-aware version of BWA to generate BAM files.³² All sequencing data was checked for concordance with SNP fingerprint data collected before sequencing.

We used HLA-HD to infer HLA genotypes from whole-genome sequencing data, starting from BAM files generated as described above.³³ HLA calls at 6-digit resolution were reduced to 4-digit level, reflecting the amino-acid sequence of the HLA protein.

Statistical analyses

The association analysis focused on ADA or NAb presence versus absence phenotypes, not considering the timing of ADA or NAb occurrence. Logistic regression was used on a per-trial basis to test for association between ADA or NAb, respectively, and HLA alleles with carrier frequencies of at least 0.5% (dominant inheritance model). We included age, sex, five principal components (PC) to correct for population stratification, and trial arm (where applicable) as covariates. We used a multi-degree-of-freedom omnibus test to test for association at multi-allelic amino acid positions in the coding region of each gene. For the meta-analyses, the random-effects model method in the R package “meta” was used to calculate effect estimates, 95% confidence intervals, and p-values.³⁴ Edginton’s method (sum of p), as implemented in the R

package “metap”, was used for meta-analysis of omnibus test results for variable amino acid positions. The Bonferroni method was applied to correct p-values for multiple testing, correcting for the number of included HLA alleles or variable amino acid positions, respectively.

Results

In total, our study included 1982 patients treated with atezolizumab as mono- or combination therapy and with available informed consent for genetic analyses. Out of these patients, 591 (29.8%) tested positive for ADA, and we observed a large variability in ADA incidences between treatment combinations and study arms (13.5% - 50.3%, Table 1). Samples from the ADA-positive patients were further tested for the presence of neutralizing antibodies (NAb), and we found that only a subset of these (N=278; 14.5%) were also NAb-positive (0% - 25.5%, Table 1).

In a meta-analysis across the eight studies, we identified a statistically significant association of five HLA class II alleles with the presence of ADA (Suppl. Results), with *HLA-DRB1*01:01* showing the strongest association ($p = 3.4 \times 10^{-5}$, OR = 1.96; Figure 1, Figure 2A). The top three alleles, *HLA-DRB1*01:01*, *HLA-DQB1*05:01*, and *HLA-DQA1*01:01* form a common HLA class II haplotype and are unlikely to be statistically independent. Indeed, *HLA-DQB1*05:01* and *HLA-DQA1*01:01* were no longer significantly associated in a conditional analysis, including *HLA-DRB1*01:01* as a covariate (Suppl. Results). We also inferred variable amino acid positions across all tested HLA genes. Position 96 of HLA-DR β 1 showed the strongest significance ($p = 4.8 \times 10^{-5}$), and glutamic acid as residue at this position was associated with increased risk for ADA (OR = 1.91; Figure 1, Figure 2A). Of all alleles tested, only *HLA-DRB1*01* alleles (*HLA-DRB1*01:01* and *HLA-DRB1*01:02*) carried this residue at position 96 (Table 2), and the amino acid residue did not explain the association better than the top-associated allele (Figure 1). Conditional analysis, including the top-associated position as covariate, did not yield further amino acid positions that were independently associated.

Next, we focused on patients with NAb (N = 278), excluding individuals with ADA that were not neutralizing from the analysis. The top-associated HLA allele with NAb status was *HLA-DQA1*01:01* ($p = 2.8 \times 10^{-7}$, OR = 2.31; Figure 1, Figure 2B), a member of the same common haplotype that includes *HLA-DRB1*01:01*. In fact, *HLA-DRB1*01:01* was the second strongest associated allele ($p = 1.6 \times 10^{-6}$, OR = 2.32) in the NAb analysis (Figure 1, Figure 2B). On amino acid level, position 96 of HLA-DR β 1 again showed the strongest association ($p = 3.2 \times 10^{-5}$), with glutamic acid mediating increased risk for NAb development (OR = 2.33, Figure 1, Figure 2B). Conditional analysis revealed no statistically independent associations at the HLA allele or amino acid level.

Both ADA and NAb analyses yielded associations of the same group of alleles and amino acid positions, suggesting that the ADA associations are explained by the subset of patients exhibiting NAb. We therefore also investigated possible HLA associations with non-neutralizing ADA only (N = 313), and did not obtain significant results on allele or amino acid level after multiple testing correction. *HLA-DRB1*01:01* and *HLA-DQA1*01:01* yielded p values of 0.047 and 0.18, respectively, suggesting that ADA associations are predominantly driven by NAb status (Suppl. Results).

Discussion

Although the formation of ADA is associated with many or most therapeutic antibodies, little is known about the risk factors that predispose individual patients or therapeutic antibodies to their elicitation. Moreover, ADA can exhibit variable effects, with some manifesting as antibodies that do not interfere with therapeutic efficacy, while others are neutralizing *in vivo* and therefore have greater potential to attenuate efficacy. Given that we were able to analyze a large patient cohort, our study presents clear evidence for an association of common HLA class II variation with anti-atezolizumab ADA risk. *HLA-DRB1*01:01* and *HLA-DQA1*01:01* were the top-associated alleles for ADA and NAb status, respectively. Both occur together on a common HLA class II haplotype, and each showed statistically significant association with both phenotypes. This is consistent with a single amino acid position and residue (glutamic acid at HLA-DR β 1 position 96)

being most strongly associated with both ADA and NAb status. Also, no significant associations were obtained when considering only patients who exhibited non-neutralizing antibodies. Thus, most of the association with ADA can be explained by the NAb subset. 47.2% of ADA-positive patients (278 of 591) carried detectable antibodies that are neutralizing *in vitro*, suggesting a certain degree of variation in antibody clonality. The possibility that HLA class II proteins including the associated alpha or beta subunits result in the presentation of a peptide that specifically contributes to NAb formation is consistent with the fact that different atezolizumab peptides are presented by different allelic variants of HLA proteins.

Across the eight studies, 81% of patients identified as White / European (Suppl. Table 1). Both identified risk alleles show the highest carrier frequencies in White / European reference populations. *HLA-DRB1*01:01* is significantly less common for example in African American and Chinese individuals.³⁵ Due to the low number of non-European patients, our study was probably underpowered to establish possible additional associations of ADA status with HLA alleles that are frequent in such populations, but rare in Europeans. Future studies in more diverse populations will be required to answer this question. To exclude the possibility that our significant results were due to population stratification, we included five genetic principal components as covariates in all statistical analyses.

Of note, effect directionality was consistent across the investigated trials, providing evidence that the associations are specific to the treatment, but independent of cancer indication. In terms of effect estimates, the odds ratios for associated alleles in the range of 2 are comparable to reported HLA associations with ADA development for other biologics.⁹⁻¹² This implies that carrying a risk genotype is neither necessary nor sufficient to predict development of ADA. It is more likely one out of many factors that together determine ADA risk, and many of these factors remain to be uncovered.^{36,37} However, the identification of HLA risk genotypes combined with *in silico* peptide binding prediction might support efforts to identify immunogenic peptides in atezolizumab or possibly in other antibodies or protein biologics. In conclusion, our results provide strong evidence that HLA allelic variation can contribute to the development of ADAs in patients treated with therapeutic antibodies. It will be important

to assess whether similar associations exist in patient groups treated with other therapeutic antibodies that are known to elicit ADA.

Funding:

This research received no external funding.

Data availability:

HLA association summary statistics are available as Supplementary Results. Qualified researchers may request access to individual patient data used in this study through Roche's data sharing platforms in accordance with the Global Policy on Sharing of Clinical Study Information:

http://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm

Whole genome sequencing data collected in this study is available under restricted access for biomedical research use only. Applications for access to individual level data should be made to the corresponding author by email (hammer.christian@gene.com). Access to individual level data will require applicants to establish a data sharing agreement with Roche/Genentech to ensure compliance with patient consent and confidentiality obligations.

Table 1 Number of Patients with Available HLA Allele Data, as well as ADA and NAb Frequencies

Study name (Study ID)	Indication	Treatment	n ADA Results	n ADA+ (%)	n NAb Results	n NAb+ (%)
IMvigor211 (GO29436)	Urothelial Cancer	Atezolizumab	216	78 (36.1%)	208	40 (19.2%)
IMmotion151 (WO29637)	Renal Cancer	Atezolizumab + Bev	243	57 (23.5%)	242	47 (19.4%)
IMpassion130 (WO29522)	TNBC	Atezolizumab + Nab-Paclitaxel	237	32 (13.5%)	233	15 (6.4%)
IMpower130 (GO29537)	NSCLC	Atezolizumab + Nab-Paclitaxel+CarboP	215	45 (20.9%)	208	16 (7.7%)
IMpower131 (GO29437)	NSCLC	All Atezolizumab treated	360	132 (36.7%)	357	54 (15.1%)
		Atezolizumab + Nab-Paclitaxel + CarboP	185	44 (23.8%)	184	14 (8.2%)
		Atezolizumab + Paclitaxel + CarboP	175	88 (50.3%)	173	40 (23.1%)
IMpower132 (GO29438)	NSCLC	All Atezolizumab treated	138	49 (35.5%)	137	30 (21.9%)
		Atezolizumab + Pemetrexed + CisP	48	16 (33.3%)	47	12 (25.5%)
		Atezolizumab + Pemetrexed + CarboP	90	33 (36.7%)	90	18 (20.0%)
IMpower150 (GO29436)	NSCLC	All Atezolizumab treated	481	185 (38.5%)	436	76 (17.4%)
		Atezolizumab + Bev + Paclitaxel + CarboP	229	89 (38.9%)	207	36 (17.4%)
		Atezolizumab + Paclitaxel + CarboP	252	96 (38.1%)	229	40 (17.5%)
IMpower133 (GO30081)	SCLC	Atezolizumab + CarboP + Etoposide	92	13 (14.1%)	91	0 (0%)
All		All Atezolizumab treated	1982	591 (29.8%)	1912	278 (14.5%)

ADA=anti-drug antibodies; Bev=bevacizumab; CarboP=carboplatin; CisP=cisplatin; NAb=neutralizing antibodies; NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; TNBC=triple negative breast cancer.

Table 2 Meta-analysis association results for amino acid residues at HLA-DRβ1 position 96.


HLA-DRβ1 (96)	ADA		NAb		<i>HLA-DRB1</i> alleles (1-field) corresponding to amino-acid residue
	P	OR (95% CI)	P	OR (95% CI)	
Glutamic acid	1.89E-04	1.91 (1.57-2.25)	1.94E-07	2.33 (2.01-2.65)	*01
Histidine	0.56	1.11 (0.76-1.45)	0.62	0.87 (0.33-1.42)	*03,*07,*08,*09,*11,*12,*13,*14
Glutamine	0.03	0.68 (0.33-1.02)	0.10	0.66 (0.18-1.15)	*10,*15,*16
Tyrosine	0.56	1.07 (0.84-1.31)	0.78	0.95 (0.55-1.34)	*04

ADA=anti-drug antibodies; NAb=neutralizing antibodies; OR=odds ratio; CI = confidence interval.

Suppl. Table 1 Number of patients by race.

	American Indian or Alaska Native	Asian	Black or African American	Multiple	Unknown	White	TOTAL
IMmotion151	2	22	1	0	30	188	243
IMpassion130	11	44	12	0	11	159	237
IMpower150	0	49	9	1	13	409	481
IMpower130	0	5	9	1	12	188	215
IMpower131	1	39	3	3	6	308	360
IMpower132	1	17	0	0	10	110	138
IMpower133	0	15	0	0	1	76	92
IMvigor211	0	9	0	0	40	167	216
TOTAL	15	200	34	5	123	1605	1982

Figure 1 Meta-analysis summary results for the top-associated HLA alleles and amino acid residue




Forest plot showing the meta-analysis association effect estimates of the top-associated HLA alleles *HLA-DRB1*01:01* and *HLA-DQA1*01:01*, as well as amino acid residue 96E (Glutamic acid) of HLA-DRβ1, with ADA and NAb status, respectively. Bars represent 95% confidence intervals. ADA=anti-drug antibodies; NAb = *in vitro* neutralizing antibodies; OR = odds ratio; CI = confidence interval.


Figure 2 Per-study association results for the top-associated HLA alleles and amino acid residue

A Top HLA associations with ADA

HLA-DRB1*01:01




HLA-DRβ1 pos. 96E




B Top HLA associations with NAb

HLA-DQA1*01:01



HLA-DRβ1 pos. 96E



A) Forest plots showing the single study and meta-analysis effect estimates of the top-associated HLA allele *HLA-DRB1*01:01* and amino acid residue 96E (Glutamic acid) of HLA-DRβ1 with ADA status. B) Forest plots showing the single study and meta-analysis effect estimates of the top-associated HLA allele *HLA-DQA1*01:01* and amino acid residue 96E (Glutamic acid) of HLA-DRβ1 with NAb status. Squares represent relative study size; bars represent 95% confidence intervals, X-axes depict OR. ADA = anti-drug antibodies; NAb = *in vitro* neutralizing antibodies; OR = odds ratio; CI = confidence interval.

References

1. Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol* **20**, 651–668 (2020).
2. Shankar, G. *et al.* Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations. *Aaps J* **16**, 658–673 (2014).
3. Enrico, D., Paci, A., Chaput, N., Karamouza, E. & Besse, B. Anti-drug Antibodies Against Immune Checkpoint Blockers: Impairment of drug efficacy or indication of immune activation? *Clin Cancer Res Official J Am Assoc Cancer Res clincanres.2337.2019* (2019) doi:10.1158/1078-0432.ccr-19-2337.
4. Davda, J. *et al.* Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. *J Immunother Cancer* **7**, 105 (2019).
5. Lamberth, K. *et al.* Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. *Sci Transl Med* **9**, eaag1286 (2017).
6. Yanover, C., Jain, N., Pierce, G., Howard, T. E. & Sauna, Z. E. Pharmacogenetics and the immunogenicity of protein therapeutics. *Nat Biotechnol* **29**, 870–873 (2011).
7. Kong, S., Heinzmann, D., Lauer, S. & Lu, T. Weighted Approach for Estimating Effects in Principal Strata with Missing Data for a Categorical Post-Baseline Variable in Randomized Controlled Trials. *Arxiv* (2021).
8. Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat Rev Immunol* **18**, 325–339 (2018).
9. Link, J. *et al.* Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis. *Plos One* **9**, e90479 (2014).
10. Liu, M. *et al.* Identification of HLA-DRB1 association to adalimumab immunogenicity. *Plos One* **13**, e0195325 (2018).
11. Sazonovs, A. *et al.* HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease. *Gastroenterology* **158**, 189–199 (2019).

12. Benucci, M. *et al.* Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. *Biologics Targets Ther* **12**, 37–41 (2018).
13. Schmid, P. *et al.* Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *New Engl J Med* **379**, 2108–2121 (2018).
14. Socinski, M. A. *et al.* Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. *New Engl J Med* **378**, 2288–2301 (2018).
15. West, H. *et al.* Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* **20**, 924–937 (2019).
16. Rini, B. I. *et al.* Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet* (2019) doi:10.1016/s0140-6736(19)30723-8.
17. Powles, T. *et al.* Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* **391**, 748–757 (2018).
18. Horn, L. *et al.* First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *New Engl J Med* **379**, 2220–2229 (2018).
19. Jotte, R. *et al.* Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. *J Thorac Oncol* **15**, 1351–1360 (2020).
20. Nishio, M. *et al.* Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial. *J Thorac Oncol* (2020) doi:10.1016/j.jtho.2020.11.025.
21. Schmid, P. *et al.* Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* **21**, 44–59 (2020).
22. Mire-Sluis, A. R. *et al.* Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. *J Immunol Methods* **289**, 1–16 (2004).

23. Gupta, S. *et al.* Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. *J Immunol Methods* **321**, 1–18 (2007).
24. Gupta, S. *et al.* Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. *J Pharmaceut Biomed* **55**, 878–888 (2011).
25. FDA Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-assessment-therapeutic-protein-products> (2014).
26. FDA Guidance for Industry: Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detection. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug> (2019).
27. Stroh, M. *et al.* Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. *Clin Pharmacol Ther* **102**, 305–312 (2017).
28. Wu, B. *et al.* Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics. *Aaps J* **18**, 1335–1350 (2016).
29. DePristo, M. A. *et al.* A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* **43**, 491–498 (2011).
30. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* **20**, 1297–303 (2010).
31. Auwera, G. A. *et al.* From FastQ Data to High-Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline. *Curr Protoc Bioinform* **43**, 11.10.1-11.10.33 (2013).
32. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinform Oxf Engl* **25**, 1754–60 (2009).
33. Kawaguchi, S., Higasa, K., Shimizu, M., Yamada, R. & Matsuda, F. HLA-HD: An accurate HLA typing algorithm for next-generation sequencing data. *Hum Mutat* **38**, 788–797 (2017).
34. Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. *Évid Based Ment Heal* **22**, 153–160 (2019).

35. Gonzalez-Galarza, F. F. *et al.* Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. *Nucleic Acids Res* **48**, D783–D788 (2019).
36. Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. *Nat Rev Drug Discov* **1**, 457–462 (2002).
37. Yin, L., Chen, X., Vicini, P., Rup, B. & Hickling, T. P. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. *Cell Immunol* **295**, 118–126 (2015).